Exametazime Systemic Intravenous Use

The following adverse reactions are described elsewhere in the labeling;

• Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS].

The following adverse reactions associated with the use of technetium Tc 99m exametazime have been identified in clinical trials or post-marketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

• Cardiovascular: transient blood pressure increase.
• Skin and subcutaneous tissue disorders: rash, generalized erythema, urticaria, angioedema, pruritus.
• General disorders and administration site conditions: facial edema, fever, asthenic conditions (e.g., malaise, fatigue).
• Nervous system disorders: headache, dizziness, paresthesia.
• Vascular disorders: flushing.
• Gastrointestinal disorders: nausea, vomiting.

Read the entire FDA prescribing information for Drax Exametazime (Exametazime Systemic Intravenous Use)